Treatment regimen cut disease recurrence or death risk by 20% Researchers call data 'paradigm changing' J&J plans to seek expanded approvals for Erleada May 31 (Reuters) - Johnson & Johnson's (JNJ.N), ...

A previous trial involving patients with metastatic prostate cancer that was resistant to androgen pathway modulation (formerly referred to as castration-resistant) showed that adding talazoparib ...

Radical prostatectomy is potentially curative in patients with high-risk localized or locally advanced prostate cancer; however, relapse occurs within 5 years in up to 50% of patients. We conducted a ...

Columbia University scientists say they have homed in on a gene that appears to drive one of the deadliest forms of prostate cancer, and shutting it down in mice made stubborn tumors shrink. The work ...

Research found that the weight-loss medications may reduce the spread of several obesity-related cancers, including lung, ...

The cognitive effects men with advanced prostate cancer experience during treatment may vary based on the therapy they ...

Over half of patients in a randomized trial switch from enzalutamide to darolutamide because of cognitive issues; no one switches in the opposite direction.

Rutgers Cancer Institute, New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center, together with RWJBarnabas Health, will have a significant presence at this year's meeting ...

GLP-1 receptor agonists may help mitigate progression of at least some obesity-related cancers, according to retrospective ...

A new blood test could help doctors identify whether a treatment for advanced prostate cancer is failing weeks earlier than ...

Novartis today announced new data from PSMAddition demonstrating improved prostate-specific antigen (PSA) responses with ...

Prostate-specific antigen (PSA) blood testing likely reduces the risk of death from prostate cancer, found a new review ...